Idorsia Ltd (OTCMKTS:IDRSF) Receives $23.00 Consensus Price Target from Analysts

Idorsia Ltd (OTCMKTS:IDRSFGet Rating) has been given a consensus rating of “Hold” by the six research firms that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $23.00.

IDRSF has been the topic of several recent analyst reports. Credit Suisse Group downgraded shares of Idorsia from an “outperform” rating to a “neutral” rating in a research note on Thursday, November 10th. Deutsche Bank Aktiengesellschaft downgraded shares of Idorsia from a “buy” rating to a “hold” rating in a research report on Friday, October 21st. JPMorgan Chase & Co. reduced their price target on shares of Idorsia from CHF 17 to CHF 15 and set a “neutral” rating on the stock in a research report on Tuesday, January 3rd. Finally, Jefferies Financial Group downgraded shares of Idorsia from a “buy” rating to a “hold” rating in a research report on Wednesday, January 18th.

Idorsia Stock Performance

Shares of OTCMKTS:IDRSF opened at $19.14 on Wednesday. Idorsia has a 52 week low of $11.62 and a 52 week high of $23.50. The company’s fifty day moving average is $15.47 and its 200-day moving average is $14.60.

Idorsia Company Profile

(Get Rating)

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus.

Read More

Analyst Recommendations for Idorsia (OTCMKTS:IDRSF)

Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.